Fozicard pills 10mg, 28pcs

Composition

1 tablet contains:

fosinopril sodium 10 mg.

Auxiliary substances:

lactose monohydrate,

croscarmellose sodium,

pregelatinized corn starch (starch 1500),

microcrystalline cellulose,

glycerol dibegenate.

Pharmacological action

Fosicard is an ACE inhibitor. Fosinopril is an ester from which the active metabolite fosinoprilate is formed in the body.

Fosinoprilate prevents the conversion of angiotensin I to the vasoconstrictor angiotensin II, which leads to vasodilation, a decrease in OPSS and a decrease in aldosterone secretion.

Due to a decrease in the secretion of aldosterone, there is a slight increase in the content of potassium ions in the serum with a simultaneous loss of sodium ions and fluid from the body.

The drug has antihypertensive, vasodilating, diuretic and potassium-sparing effects.

The antihypertensive effect is also due to the suppression of bradykinin metabolism, which has a pronounced vasodilating effect.

A decrease in blood pressure is not accompanied by changes in BCC, cerebral and renal blood flow, blood supply to internal organs, skeletal muscles, skin, and myocardial reflex activity.

The antihypertensive effect of the drug persists with long-term treatment, tolerance to the drug does not develop.

After oral use, the antihypertensive effect develops within 1 hour, reaches a maximum in 2-6 hours and persists for 24 hours.

Indications

-Arterial hypertension.

– Chronic heart failure (as part of combination therapy).

Contraindications

-Hereditary or idiopathic angioedema (including in the anamnesis) after taking other ACE inhibitors. – Pregnancy. – The period of lactation (breastfeeding). – Children and teenagers under 18 years of age. – Hypersensitivity to fosinopril and other components of the drug. The drug should be used with caution in the following cases: : – Kidney failure. – Hyponatremia (risk of dehydration, hypotension, chronic renal failure). – Bilateral renal artery stenosis or stenosis of the artery of a single kidney. – Aortic stenosis. – Condition after kidney transplantation. – Desensitization. – Systemic connective tissue diseases, including SLE, scleroderma (increased risk of neutropenia or agranulocytosis). – Hemodialysis. – Cerebrovascular diseases (including cerebrovascular insufficiency). – IHD. – Chronic heart failure of functional class III and IV according to NYHA classification. – Diabetes mellitus. – Inhibition of bone marrow hematopoiesis. – Hyperkalemia. – Elderly patients. – If you follow a salt-restricted diet. – In conditions accompanied by a decrease in BCC (including diarrhea, vomiting).

Side effects

From the cardiovascular system: low blood pressure, orthostatic hypotension, tachycardia, palpitations, arrhythmias, angina pectoris, myocardial infarction, chest pain.

From the digestive system: nausea, vomiting, constipation, intestinal obstruction, stomatitis, glossitis, dyspepsia, abdominal pain, anorexia, cholestatic jaundice, pancreatitis, hepatitis.

Respiratory system disorders: dry cough, shortness of breath, pharyngitis, laryngitis, sinusitis, pulmonary infiltrates, bronchospasm, dysphonia.

From the urinary system: development or aggravation of symptoms of chronic renal failure, proteinuria, oliguria.

From the central nervous system and peripheral nervous system: stroke, cerebral ischemia, dizziness, headache, weakness; when used in high doses – insomnia, anxiety, depression, confusion, paresthesia.

Sensory disorders: hearing and vision disorders, tinnitus, vestibular disorders.

Allergic reactions: skin rash, pruritus, angioedema.

From the laboratory parameters: hypercreatininemia, increased urea concentration, increased activity of hepatic transaminases, hyperbilirubinemia, hyperkalemia, hyponatremia, decreased hemoglobin and hematocrit concentrations, neutropenia, leukopenia, eosinophilia, increased ESR.

Interaction

Antihypertensive agents, diuretics, opioid analgesics, and general anaesthetics when used concomitantly with Fozicard enhance its hypotensive effect. NSAIDs and estrogenic drugs, when used simultaneously, reduce the severity of the antihypertensive effect of Fozicardia.

Concomitant use of Fosicard with potassium preparations, potassium-sparing diuretics increases the risk of hyperkalemia.

Fozicard enhances the hypoglycemic effect of sulfonylureas and insulin derivatives.

Concomitant use of Fosicard with allopurinol, cytostatic drugs, immunosuppressants, procainamide increases the risk of developing leukopenia.

When taking Fozicard with lithium salts at the same time, it is possible to increase the concentration of lithium in the blood.

How to take, course of use and dosage

With arterial hypertension:  before starting treatment for arterial hypertension, if possible, the previously used antihypertensive treatment should be discontinued several days before the start of taking Fozicard.

The initial dose is 10 mg 1 time/day. In the future, the dose should be selected depending on the dynamics of lowering blood pressure.

The average maintenance dose is 10-40 mg once a day. In the absence of a positive effect from Fosicard monotherapy, additional diuretics may be prescribed.

If treatment with Fosicard is started against the background of diuretic therapy, then its initial dose should not exceed 10 mg with careful medical supervision.

In the treatment of chronic heart failure, the initial dose of Fosicard is 10 mg 1 time/day.

Further, the dose of the drug is selected in accordance with the dynamics of therapeutic effectiveness, increasing by 10 mg at weekly intervals. The maximum dose is 40 mg / day. Additional use of diuretics is possible.

Overdose

Symptoms:  marked decrease in blood pressure, bradycardia, shock, impaired water-electrolyte balance, acute renal failure, stupor.

Treatment:  stop taking the drug, place the patient in a supine position with raised legs. In mild cases of overdose-gastric lavage, use of sorbents and sodium sulfate within 30 minutes after ingestion. With a decrease in blood pressure-intravenous use of catecholamines, angiotensin II; with bradycardia – the use of a pacemaker. Hemodialysis is ineffective.

Special instructions

Patients with severe hypertension or concomitant decompensated chronic heart failure should start treatment with Fosicard in a hospital setting.

Before and during treatment with the drug, it is necessary to monitor blood pressure, kidney function, potassium concentration, hemoglobin, creatinine, urea, electrolyte concentration and liver enzyme activity in the blood.

While taking Fozicard, the number of white blood cells in the peripheral blood should be periodically monitored, especially in patients with an increased risk of neutropenia (with impaired renal function and systemic connective tissue diseases).

Due to the increased risk of hypotension, caution should be exercised when prescribing the drug to patients on a low-salt or salt-free diet.

Form of production

Pills.

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

2 years

Active ingredient

Fosinopril

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as directed by your doctor

Indications

Hypertension, Heart Failure